Date on which the corporate action was made public: 17 December 2024.

Reverse split ratio: 15 old shares give 1 new share.

Last day including right: 13 January 2025.

Ex-date: 14 January 2025.

Record date: 15 January 2025.

Date of approval: 7 January 2025.

Other information (optional): A new ISIN number will be issued for the shares.
Further information will be provided in a separate stock exchange announcement.

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on the Oslo Stock Exchange and
Euronext Expand.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.